On November 7, 2024, BioVie Inc., a biopharmaceutical company, conducted its 2024 Annual Meeting of Stockholders. During the meeting, all of BioVie's director nominees were elected for one-year terms. The company also secured approval for the ratification of EisnerAmper LLP as its independent registered public accounting firm for the fiscal year 2025. Additionally, stockholders approved a non-binding advisory proposal on executive compensation and the amendment and restatement of the 2019 Omnibus Equity Incentive Plan, which increases the number of shares authorized for issuance to 1,250,000. The meeting saw a significant number of broker non-votes, but the resolutions were passed with a majority of for votes.

On November 7, 2024, BioVie Inc., a biopharmaceutical company, conducted its 2024 Annual Meeting of Stockholders. During the meeting, all of BioVie's director nominees were elected for one-year terms. The company also secured approval for the ratification of EisnerAmper LLP as its independent registered public accounting firm for the fiscal year 2025. Additionally, stockholders approved a non-binding advisory proposal on executive compensation and the amendment and restatement of the 2019 Omnibus Equity Incentive Plan, which increases the number of shares authorized for issuance to 1,250,000. The meeting saw a significant number of broker non-votes, but the resolutions were passed with a majority of for votes.